FinBoss.io
CSEN
Dashboards
  • Investor
  • Trader
  • Beginner
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
    • Stock indices
    • Commodities
    • Forex rates
    • Bear market radar
    • Famous investors' portfolios
  • Tools
  • Guides
  • FinBot
FinBoss.io
CSEN
Home
Stocks
Dexcom Inc
DX

Dexcom Inc

DXCMHealth care

Stock · Data from SEC EDGAR 13F · Held by 14 of 87 tracked investors

$84.24
▼ 0.62%
Famous investorshold 14buying 0selling 1
Price (USD)
$84.24
Market cap
$31.4B
P/E ratio
33.2
Tracked investors holding
14 of 87
Next earnings
–

Dexcom Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
82out of 100
  • Valuation43
  • Growth85
  • Profitability82
  • Quality94
  • Debt100
  • Stability89
In its favour
  • Out of 100 USD of revenue, 19 USD is left as net profit.

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Sep 202629 Oct 20260.730.66+10.6%
Jun 202630 Jul 20260.700.61+14.8%
Mar 202630 Apr 20260.560.47+19.2%
Dec 202512 Feb 20260.680.65+4.6%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

7D
+7.89%
1M
-2.46%
3M
+0.01%
YTD
+27.38%
1Y
+54.11%
3Y
-13.03%
5Y
-46.65%
Forward P/E
27
Dividend yield
–
52-week low
$54.11
52-week high
$92.59

Chart DXCM

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

14
JS
Jim Simons
Renaissance Technologies
0.15%$109,834,111▲ +3%
RD
Ray Dalio
Bridgewater Associates
0.11%$27,002,568▲ +187%
CA
Cliff Asness
AQR Capital Management
0.08%$218,060,428▲ +49%
Ns
Norský státní fond
Norges Bank
0.05%$462,565,862New position
Čn
Česká národní banka
Česká národní banka
0.05%$9,355,993▼ -1.3%
Šn
Švýcarská národní banka
Swiss National Bank
0.04%$73,108,425▼ -5.2%
MG
Mario Gabelli
GAMCO Investors
0.03%$3,502,200unchanged
JG
Joel Greenblatt
Gotham Asset Management
0.02%$6,903,375▼ -5.1%
SC
Steven Cohen
Point72 Asset Management
0.02%$19,049,274▲ +9.9%
RB
Ron Baron
Baron Capital
0.02%$16,500,750▲ +1.7%
KG
Ken Griffin
Citadel Advisors
0.01%$81,612,507▼ -42.1%
IE
Israel Englander
Millennium Management
0.01%$26,629,651▼ -75.6%
JY
Jeff Yass
Susquehanna International Group
0.01%$70,304,241▲ +175.6%
KF
Ken Fisher
Fisher Investments
0%$4,115,723▼ -67.6%

Frequently asked questions

How much is Dexcom Inc (DXCM) stock?

Dexcom Inc shares trade at $84.24, -0.62% over the last trading day. The price is delayed.

What is the market cap of Dexcom Inc?

The market cap of Dexcom Inc is about $31.4B and its price-to-earnings ratio (P/E) is 33.2.

How has Dexcom Inc stock performed over the last year?

The Dexcom Inc share price changed by +54.11% over 12 months and by -46.65% over 5 years.

Which big investors hold Dexcom Inc?

According to the latest 13F filings, 14 of 87 tracked investors hold Dexcom Inc, for example Jim Simons, Ray Dalio, Cliff Asness.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

✓
  • ✓It earns 38 USD a year on every 100 USD of invested capital (ROE).
  • ✓It has more cash than debt.
  • ✓Revenue grew 17% a year over 3 years.
    • What to watch
    • Nothing notable from the statements.

    The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

    Is the stock expensive?

    Fairly expensive

    For 1 USD of annual earnings you pay 32.4 USD. Based on next year's estimates 26.3 USD.

    P/E
    32.4×
    P/S
    6.0×
    EV/EBITDA
    20.3×

    Is the company growing?

    Growing
    22
    23
    24
    25

    Revenue over 3 years grew 17.0% a year. Last year 11.2%.

    Does it make money?

    Good
    • Cost of sales 40
    • Research 12.9
    • Operations and selling 27.7
    • Taxes and other 1.6
    • Net profit 17.9

    Out of 100 USD of revenue, 17.9 USD is left as net profit.

    Is it financially healthy?

    Yes
    Cash
    1.8B USD
    Debt
    1.3B USD
    Free CF
    –

    It has more cash than debt.

    Does it pay a dividend?

    No dividend

    The company pays no dividend. It reinvests the money or holds it.

    What do analysts expect?

    Strong buy
    Average target
    97.23 USD
    Vs price
    +15%

    26 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    14 of 87

    Among the tracked investors, Jim Simons, Ray Dalio, Cliff Asness and others hold the stock according to 13F filings.

    Revenue and net profit (USD B)

    Margins (% of revenue)

    Free cash flow and capex (USD B)

    Cash and debt (USD B)

    Earnings per share (EPS, USD)

    Latest quarters (USD B)

    Ratios

    P/E
    32.4×
    Forward P/E
    26.3×
    P/B
    12.1×
    P/S
    6.0×
    PEG
    1.36
    EV/EBITDA
    20.3×
    Gross margin
    63.4%
    Operating margin
    24.3%
    Net margin
    19.4%
    ROE
    37.7%
    ROA
    11.1%
    Debt / equity
    0.5×
    Current ratio
    1.7×
    Revenue growth
    11.2%
    Earnings growth
    2.6%
    Beta
    1.48
    Dividend
    0.00%
    Payout ratio
    0%